| Literature DB >> 35647573 |
Itika Garg1,2, Chibuike Uwakwe1,2, Rongrong Le2,3, Edward S Lu1,2, Ying Cui2,4, Karen M Wai1,2, Raviv Katz1,2, Ying Zhu2,5, Jade Y Moon1,2, Chloe Y Li2, Inês Laíns1,2, Dean Eliott1, Tobias Elze6, Leo A Kim1,6, David M Wu1, Joan W Miller1, Deeba Husain1, Demetrios G Vavvas1, John B Miller1,2.
Abstract
Purpose: To study the wider field swept-source optical coherence tomography angiography (WF SS-OCTA) metrics, especially non-perfusion area (NPA), in the diagnosing and staging of DR. Design: Cross-sectional observational study (November 2018-September 2020). Participants: 473 eyes of 286 patients (69 eyes of 49 control patients and 404 eyes of 237 diabetic patients).Entities:
Keywords: Optical coherence tomography angiography; capillary dropout; diabetic retinopathy; diabetic retinopathy classification; diabetic retinopathy grading; diabetic retinopathy severity scale; ischemia index; non-perfusion area; quantitative vascular metrics; vessel density; vessel skeletonized density; widefield swept source optical coherence tomography angiography
Year: 2022 PMID: 35647573 PMCID: PMC9137369 DOI: 10.1016/j.xops.2022.100144
Source DB: PubMed Journal: Ophthalmol Sci ISSN: 2666-9145
Figure 1CONSORT flow diagram of study recruitment.
Figure 2Representative full-thickness 6 × 6 mm en face swept-source OCT angiography (SS-OCTA) images of control eyes and eyes from patients with diabetes with different stages of diabetic retinopathy (DR), obtained from the ARI network (Zeiss Portal v5.4-1206). Vessel density (VD) (A-E): binarized SS-OCTA images from different study groups. Vessel density heat map (F-J): color density maps with overlaying standardized ETDRS grid of the binarized images according to the VD distribution. Vessel skeletonized density (VSD) (K-O): skeletonized SS-OCTA images from different study groups. Vessel skeletonized density heat map (P-T): Color density maps with overlaying standardized ETDRS grid of the skeletonized images according to the VSD distribution. Foveal avascular zone (FAZ) (U-Y): Representative images outlining the FAZ. NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy.
Figure 3Representative full-thickness 12 × 12 mm en face swept-source OCT angiography (SS-OCTA) images of control eyes and eyes from patients with diabetes with different stages of diabetic retinopathy (DR), obtained from the ARI network (Zeiss Portal v5.4-1206). Vessel density (VD) (A-E): binarized SS-OCTA images from different study groups. Vessel density heat map (F-J): color density maps with overlaying standardized ETDRS grid of the binarized images according to the VD distribution. Vessel skeleton density (VSD) (K-O): skeletonized SS-OCTA images from different study groups. Vessel skeleton density heat map (P-T): color density maps with overlaying standardized ETDRS grid of the skeletonized images according to the VSD distribution. Foveal avascular zone (FAZ) (U-Y): representative images outlining the FAZ. Nonperfusion area (NPA) (Z-ad): Representative images from superficial capillary plexus (SCP) with NPA shaded in blue color. NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy.
Demographic Characteristics of Study Population
| Study Parameter (Median (IQR) or n (%) | Control (n = 49) | Patients with DM (n = 237) | |
|---|---|---|---|
| Age, yrs | 57 (45–63) | 59 (50–66) | 0.09 |
| Sex, Female | 19 (38.8) | 103 (43.46) | 0.66 |
| Race | |||
| White | 34 (72.3) | 129 (56.6) | |
| Black | 6 (12.8) | 46 (20.2) | |
| Asian | 3 (6.4) | 17 (7.5) | |
| Hispanic | 1 (2.1) | 34 (14.9) | |
| Other | 3 (6.4) | 2 (0.9) | |
| Smoking | 0.44 | ||
| Never | 27 (67.5) | 129 (57.3) | |
| Former | 11 (27.5) | 76 (33.8) | |
| Current | 2 (5.0) | 20 (8.9) | |
| MABP, mmHg | 97.7 (89.1–102.5) | 95.0 (86.7–104.3) | 0.50 |
| BMI, kg/m2 | 26.4 (22.7–30.3) | 30.7 (26.4–34.5) | |
| HbA1c, % | 5.6 (5.5–5.7) | 8.0 (7.0–9.3) | |
| Type of diabetes | - | ||
| 1 | 40 (16.9) | ||
| 2 | 197 (83.1) | ||
| Duration of DM, yrs | - | 19 (10–27) | |
| Received treatment with insulin | - | 171 (72.2) |
Values in bold are statistically significant (P < 0.05). BMI = body mass index (calculated as weight in kilograms divided by the square of height in meters); DM = diabetes mellitus; HbA1c = glycosylated hemoglobin; IQR = interquartile range; MABP = mean arterial blood pressure.
Race, Other: American Indian, Latino, Middle eastern, Puerto Rico.
Based on Mann–Whitney U test or Pearson’s chi-square test of association with Yates’ continuity correction, when applicable.
Clinical Characteristics of Eyes, Organized by Study Groups
| Study Parameter Median (IQR) or n (%) | Control (n = 69) | No DR (n = 51) | Mild NPDR (n = 88) | Moderate-severe NPDR (n = 97) | PDR (n = 168) | |
|---|---|---|---|---|---|---|
| IOP, mmHg | 16.0 (14.0–17.0) | 18.0 (15.0–19.0) | 17.0 (14.0–18.0) | 16.0 (15.0–19.0) | 16.0 (14.0–17.3) | |
| BCVA (logMAR) | 0.00 (0.00–0.08) | 0.02 (0.00–0.04) | 0.04 (0.00–0.14) | 0.12 (0.02–0.22) | 0.18 (0.09–0.40) | |
| Lens status | ||||||
| Pseudophakia | 3 (4.35) | 0 (0.0) | 18 (20.45) | 23 (23.71) | 70 (41.67) | |
| Phakic | 66 (95.65) | 51 (100.0) | 70 (79.55) | 74 (76.29) | 97 (57.74) | |
| Aphakia | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.60) | |
| Laterality, OD | 38 (55.1) | 25 (49.0) | 44 (50.0) | 54 (55.67) | 91 (54.17) | 0.89 |
| Prior history of focal laser | - | 0 (0.0) | 2 (2.3) | 8 (8.25) | 13 (7.7) | 0.06 |
| Prior history of PRP | - | 0 (0.0) | 1 (1.14) | 4 (4.12) | 128 (76.2) | |
| Prior history of receiving anti-VEGF injection | - | 0 (0.0) | 13 (14.8) | 24 (24.74) | 85 (50.6) | |
| Number of anti-VEGF injections, if received | - | - | 3.50 (1.0–5.25) | 3.0 (2.0–6.0) | 4.0 (2.0–7.75) | 0.40 |
| Prior history of PPV | - | 0 (0.0) | 1 (1.2) | 0 (0.0) | 39 (23.21) | |
| DME | - | 0 (0.0) | 21 (23.9) | 71 (73.20) | 91 (54.2) |
Values in bold are statistically significant (P < 0.05). BCVA = best-corrected visual acuity; DME = diabetic macular edema; DR = diabetic retinopathy; IOP = intraocular pressure; IQR = interquartile range; logMAR = logarithm of minimum angle of resolution; NPDR = nonproliferative diabetic retinopathy; OD = right eye; PDR = proliferative diabetic retinopathy; PPV = pars plana vitrectomy; PRP = panretinal photocoagulation; VEGF = vascular endothelial growth factor.
Based on Kruskal–Wallis test or Pearson’s chi-square test of association with Yates’ continuity correction, when applicable.
Mixed-Effects Multiple Linear Regression Model Results by Study Group, Adjusted for Age (Model A) and Age along with Prior Therapeutic Interventions (Model B)
| Study Parameter | Control (n = 69) | No DR (n = 51) | Mild NPDR (n = 88) | Moderate-Severe NPDR (n = 97) | PDR (n = 168) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (IQR) | Median (IQR) | Model A | Model B | Median (IQR) | Model A | Model B | Median (IQR) | Model A | Model B | Median (IQR) | Model A | Model B | |||||||
| vs. Control | vs. Control | vs. Control | vs. No DR | vs. Control | vs. No DR | vs. Control | vs. Mild NPDR | vs. Control | vs. Mild NPDR | vs. control | vs. moderate-severe NPDR | vs. control | vs. moderate-severe NPDR | ||||||
| VD (SCP) | 0.44 (0.43–0.45) | 0.44 (0.42–0.45) | −0.01 (0.33) | −0.01 (0.33) | 0.41 (0.39–0.43) | 0.40 (0.37–0.42) | −0.02 (0.052) | 0.38 (0.35–0.41) | −0.02 (0.07) | ||||||||||
| VD (DCP) | 0.29 (0.25–0.34) | 0.28 (0.23–0.34) | −0.02 (0.26) | −0.02 (0.27) | 0.23 (0.18–0.29) | 0.22 (0.16–0.27) | −0.02 (0.15) | −0.01 (0.29) | 0.20 (0.13–0.25) | −0.02 (0.13) | −0.01 (0.59) | ||||||||
| VD (Retina) | 0.46 (0.45–0.47) | 0.46 (0.45–0.47) | −0.01 (0.29) | −0.01 (0.28) | 0.44 (0.42–0.46) | −0.02 (0.051) | −0.02 (0.051) | 0.43 (0.40–0.44) | 0.42 (0.39–0.43) | −0.01 (0.12) | |||||||||
| VSD (SCP) | 19.76 (19.01–20.39) | 19.58 (18.73–20.38) | −0.40 (0.36) | −0.38 (0.36) | 18.54 (17.27–19.57) | 17.71 (16.35–18.58) | 16.88 (15.28–17.94) | ||||||||||||
| VSD (DCP) | 14.34 (12.41–16.67) | 13.89 (11.67–16.45) | −0.90 (0.25) | −0.89 (0.26) | 11.23 (8.78–14.07) | 10.62 (7.56–12.82) | −1.08 (0.09) | −0.84 (0.19) | 9.71 (6.31–12.08) | −0.94 (0.09) | −0.56 (0.46) | ||||||||
| VSD (Retina) | 20.79 (20.24–21.34) | 20.58 (20.24–21.24) | −0.38 (0.35) | −0.37 (0.34) | 19.75 (18.87–20.58) | 18.81 (17.64–19.88) | 18.00 (16.74–19.03) | ||||||||||||
| FAZ Area | 0.26 (0.17–0.34) | 0.25 (0.19–0.36) | −0.01 (0.92) | −0.01 (0.90) | 0.33 (0.18–0.42) | 0.05 (0.49) | 0.06 (0.47) | 0.05 (0.45) | 0.06 (0.42) | 0.30 (0.21–0.48) | 0.09 (0.20) | 0.04 (0.55) | 0.08 (0.25) | 0.03 (0.69) | 0.34 (0.23–0.48) | 0.16 (0.057) | −0.08 (0.25) | ||
| FAZ Perimeter | 2.09 (1.74–2.39) | 2.04 (1.77–2.93) | −0.08 (0.82) | −0.08 (0.82) | 2.29 (1.76–2.93) | 0.28 (0.35) | 0.36 (0.29) | 0.30 (0.32) | 0.38 (0.26) | 2.52 (1.91–3.11) | 0.47 (0.12) | 0.18 (0.52) | 0.43 (0.15) | 0.13 (0.64) | 2.56 (2.02–3.37) | 0.59 (0.09) | |||
| FAZ Circularity | 0.75 (0.69–0.79) | 0.76 (0.69–0.79) | −0.01 (0.67) | −0.01 (0.67) | 0.69 (0.59–0.76) | −0.05 (0.058) | −0.04 (0.21) | −0.05 (0.052) | −0.04 (0.19) | 0.63 (0.55–0.71) | −0.03 (0.31) | −0.02 (0.44) | 0.62 (0.51–0.73) | −0.06 (0.050) | |||||
| VD (SCP) | 0.37 (0.35–0.39) | 0.36 (0.32–0.39) | −0.01 (0.46) | −0.01 (0.45) | 0.35 (0.28–0.37) | 0.34 (0.29–0.37) | 0.01 (0.67) | −0.01 (0.53) | 0.30 (0.26–0.34) | −0.02 (0.20) | |||||||||
| VD (DCP) | 0.22 (0.18–0.27) | 0.20 (0.17–0.26) | −0.004 (0.85) | −0.004 (0.84) | 0.17 (0.10–0.22) | 0.16 (0.10–0.22) | −0.002 (0.87) | −0.001 (0.95) | 0.13 (0.09–0.18) | −0.02 (0.14) | −0.01 (0.45) | ||||||||
| VD (Retina) | 0.41 (0.38–0.43) | 0.40 (0.37–0.42) | −0.01 (0.69) | −0.01 (0.68) | 0.38 (0.31–0.40) | 0.37 (0.31–0.39) | −0.000 (0.97) | −0.002 (0.88) | 0.34 (0.29–0.38) | −0.02 (0.054) | −0.01 (0.39) | ||||||||
| VSD (SCP) | 13.27 (12.08–13.94) | 12.80 (11.33–13.79) | −0.39 (0.51) | −0.39 (0.50) | 12.18 (9.78–13.08) | 11.90 (10.10–12.67) | 0.12 (0.79) | 0.22 (0.62) | 10.52 (8.91–11.85) | −0.74 (0.14) | |||||||||
| VSD (DCP) | 8.31 (6.45–9.90) | 7.38 (5.93–9.25) | −0.31 (0.65) | −0.32 (0.65) | 6.16 (3.55–8.18) | 5.53 (3.61–7.80) | −0.21 (0.68) | −0.18 (0.73) | 4.68 (3.33–6.60) | −0.67 (0.14) | −0.46 (0.43) | ||||||||
| VSD (Retina) | 14.56 (13.42–15.33) | 14.30 (12.88–15.20) | −0.32 (0.62) | −0.32 (0.61) | 13.33 (11.09–14.26) | 12.96 (10.75–13.79) | −0.01 (0.98) | 0.11 (0.81) | 11.77 (10.03–13.11) | −0.81 (0.051) | −0.53 (0.33) | ||||||||
| FAZ Area | 0.27 (0.20–0.35) | 0.28 (0.20–0.41) | 0.07 (0.86) | 0.07 (0.86) | 0.39 (0.26–0.54) | 0.59 (0.08) | 0.52 (0.20) | 0.59 (0.08) | 0.51 (0.20) | 0.32 (0.20–0.47) | 0.24 (0.47) | −0.35 (0.26) | 0.23 (0.50) | −0.36 (0.25) | 0.34 (0.21–0.52) | 0.58 (0.06) | 0.33 (0.23) | 0.46 (0.26) | 0.23 (0.54) |
| FAZ Perimeter | 2.25 (1.70–2.59) | 2.44 (1.91–3.00) | 0.38 (0.76) | 0.39 (0.75) | 2.83 (2.15–3.45) | 1.85 (0.12) | 1.84 (0.12) | 2.61 (1.99–3.54) | 1.22 (0.22) | −1.01 (0.27) | 1.18 (0.24) | −1.05 (0.26) | 2.59 (1.99–3.54) | 0.68 (0.40) | 1.90 (0.12) | 0.72 (0.51) | |||
| FAZ Circularity | 0.68 (0.63–0.72) | 0.64 (0.55–0.74) | −0.04 (0.34) | −0.04 (0.31) | 0.61 (0.52–0.69) | −0.06 (0.09) | −0.06 (0.09) | 0.53 (0.41–0.66) | −0.04 (0.14) | −0.04 (0.18) | 0.59 (0.48–0.65) | 0.02 (0.37) | −0.01 (0.74) | ||||||
| NPA, Superficial slab | 0.20 (0.04–0.40) | 0.26 (0.12–0.74) | 1.47 (0.54) | 1.37 (0.56) | 5.41 (2.64–10.45) | 9.88 (5.61–18.04) | 17.15 (11.37–28.93) | 3.07 (0.13) | |||||||||||
Values in bold are statistically significant (P < 0.05). DCP = deep capillary plexus; DR = diabetic retinopathy; FAZ = foveal avascular zone; IQR = interquartile range; NPA = nonperfusion area; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; SCP = superficial capillary plexus; VD = vessel density; VSD = vessel skeletonized density. Therapeutic interventions are prior history of focal laser, prior history of panretinal photocoagulation, prior history of anti-vascular endothelial growth factor injections received, and prior history of pars plana vitrectomy.
Figure 4Boxplots of quantitative vascular metrics measured on wider field (WF) swept-source OCT angiography (SS-OCTA) (A), vessel density (VD) (B), foveal avascular zone (FAZ) area, mm2; FAZ perimeter, mm; and FAZ circularity (C) vessel skeleton density (VSD), mm-1(D) nonperfusion area (NPA) (12 × 12), mm2. 6 × 6 = 6 × 6 mm angiogram size; 12 × 12 = 12 × 12 mm angiogram size. DCP = deep capillary plexus; DR = diabetic retinopathy; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; SCP = superficial capillary plexus. ∗P < 0.05 on mixed-effects multiple linear regression analyses, controlling for age.
Results of Quantitative Analyses of Eye with and without Diabetic Macular Edema within the Same Study Group Using Mixed Effects Multiple Linear Regression with Post Hoc Tukey’s Honest Significant Differences Test, Adjusting for Age (Model A) and Age Along with Prior Therapeutic Interventions (Model B)
| Angiogram | Study Parameter | Presence of DME (Ref: DME absent) | Model A | Model B | ||
|---|---|---|---|---|---|---|
| β | β | |||||
| 6 × 6 mm | VD (SCP) | Mild NPDR | −0.02 | 0.10 | −0.02 | 0.07 |
| Moderate-severe NPDR | ||||||
| PDR | 0.004 | 0.64 | 0.002 | 0.83 | ||
| VD (DCP) | Mild NPDR | |||||
| Moderate-severe NPDR | 0.03 | 0.18 | 0.03 | 0.18 | ||
| PDR | −0.001 | 0.92 | −0.003 | 0.80 | ||
| VD (Retina) | Mild NPDR | −0.02 | 0.18 | −0.02 | 0.12 | |
| Moderate-severe NPDR | ||||||
| PDR | −0.002 | 0.68 | −0.005 | 0.54 | ||
| VSD (SCP) | Mild NPDR | −0.80 | 0.14 | −0.99 | 0.09 | |
| Moderate-severe NPDR | ||||||
| PDR | 0.06 | 0.86 | −0.01 | 0.97 | ||
| VSD (DCP) | Mild NPDR | |||||
| Moderate-severe NPDR | 1.30 | 0.17 | 1.34 | 0.17 | ||
| PDR | −0.10 | 0.88 | −0.20 | 0.77 | ||
| VSD (Retina) | Mild NPDR | −0.72 | 0.15 | −0.88 | >0.99 | |
| Moderate-severe NPDR | ||||||
| PDR | −0.28 | 0.39 | −0.35 | 0.32 | ||
| FAZ Area | Mild NPDR | 0.01 | 0.94 | 0.18 | 0.71 | |
| Moderate-severe NPDR | −0.56 | 0.22 | ||||
| PDR | −0.08 | 0.21 | −0.23 | 0.47 | ||
| FAZ Perimeter | Mild NPDR | 0.06 | 0.89 | 0.03 | 0.75 | |
| Moderate-severe NPDR | −0.61 | 0.17 | −0.18 | 0.07 | ||
| PDR | −0.30 | 0.30 | −0.06 | 0.40 | ||
| FAZ Circularity | Mild NPDR | |||||
| Moderate-severe NPDR | 0.02 | 0.66 | 0.02 | 0.70 | ||
| PDR | −0.03 | 0.27 | −0.03 | 0.26 | ||
| 12 × 12 mm | VD (SCP) | Mild NPDR | −0.002 | 0.19 | −0.03 | 0.18 |
| Moderate-severe NPDR | 0.003 | 0.06 | 0.03 | 0.07 | ||
| PDR | −0.001 | 0.27 | −0.01 | 0.31 | ||
| VD (DCP) | Mild NPDR | −0.001 | 0.43 | −0.01 | 0.53 | |
| Moderate-severe NPDR | 0.002 | 0.24 | 0.03 | 0.20 | ||
| PDR | −0.001 | 0.40 | −0.01 | 0.58 | ||
| VD (Retina) | Mild NPDR | −0.03 | 0.16 | −0.03 | 0.18 | |
| Moderate-severe NPDR | 0.03 | 0.07 | 0.04 | 0.08 | ||
| PDR | −0.02 | 0.11 | −0.02 | 0.18 | ||
| VSD (SCP) | Mild NPDR | −1.31 | 0.057 | |||
| Moderate-severe NPDR | 1.25 | 0.051 | 1.30 | 0.056 | ||
| PDR | −0.55 | 0.22 | −0.52 | 0.29 | ||
| VSD (DCP) | Mild NPDR | −0.11 | 0.88 | −0.06 | 0.94 | |
| Moderate-severe NPDR | 0.87 | 0.25 | 0.97 | 0.22 | ||
| PDR | −0.45 | 0.40 | −0.34 | 0.55 | ||
| VSD (Retina) | Mild NPDR | |||||
| Moderate-severe NPDR | 1.28 | 0.06 | 1.41 | 0.058 | ||
| PDR | −0.81 | 0.10 | −0.69 | 0.20 | ||
| FAZ Area | Mild NPDR | −0.35 | 0.46 | −1.14 | 0.47 | |
| Moderate-severe NPDR | −0.46 | 0.34 | −2.04 | 0.19 | ||
| PDR | 0.06 | 0.85 | −0.08 | 0.94 | ||
| FAZ Perimeter | Mild NPDR | −0.99 | 0.48 | −0.42 | 0.44 | |
| Moderate-severe NPDR | −1.79 | 0.20 | −0.53 | 0.33 | ||
| PDR | 0.28 | 0.78 | −0.03 | 0.94 | ||
| FAZ Circularity | Mild NPDR | −0.02 | 0.57 | −0.03 | 0.51 | |
| Moderate-severe NPDR | 0.05 | 0.28 | 0.05 | 0.24 | ||
| PDR | −0.02 | 0.46 | −0.002 | 0.96 | ||
| Nonperfusion area | Mild NPDR | 0.76 | 0.76 | 0.41 | 0.89 | |
| Moderate-severe NPDR | −0.68 | 0.79 | −0.74 | 0.79 | ||
| PDR | 2.27 | 0.21 | 3.08 | 0.13 | ||
Values in bold are statistically significant (P < 0.05). DCP = deep capillary plexus; DME = diabetic macular edema; FAZ = foveal avascular zone; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; SCP = superficial capillary plexus; VD = vessel density; VSD = vessel skeletonized density. Therapeutic interventions include prior history of focal laser, prior history of panretinal photocoagulation, prior history of anti-vascular endothelial growth factor injections received, and prior history of pars plana vitrectomy.
Area Under the Receiver Operator Curve Analyses Comparing the Accuracy of Each Quantitative Metric and Angiogram for Predicting the Presence of DR and Between Its Different Stages
| Study Parameter | Presence of DR vs. Absence of DR | No DR vs. Controls | Mild NPDR | Moderate-Severe NPDR | PDR | |||
|---|---|---|---|---|---|---|---|---|
| vs. Controls | vs. No DR | vs. Controls | vs. Mild NPDR | vs. Controls | vs. Moderate-severe NPDR | |||
| 6 × 6 mm, AUC (95% CI) | ||||||||
| VD (SCP) | 0.54 (0.43–0.64) | 0.74 (0.67–0.82) | 0.69 (0.60–0.78) | 0.62 (0.54–0.70) | 0.62 (0.56–0.70) | |||
| VD (DCP) | 0.76 (0.71–0.81) | 0.54 (0.43–0.65) | 0.72 (0.64–0.80) | 0.66 (0.56–0.76) | 0.78 (0.71–0.85) | 0.56 (0.47–0.64) | 0.56 (0.49–0.64) | |
| VD (Retina) | 0.56 (0.46–0.67) | 0.76 (0.69–0.84) | 0.71 (0.62–0.80) | 0.65 (0.57–0.73) | 0.63 (0.56–0.70) | |||
| VSD (SCP) | 0.53 (0.43–0.64) | 0.74 (0.66–0.82) | 0.69 (0.60–0.77) | 0.65 (0.57–0.73) | 0.64 (0.57–0.71) | |||
| VSD (DCP) | 0.77 (0.72–0.82) | 0.54 (0.43–0.64) | 0.72 (0.64–0.80) | 0.67 (0.58–0.77) | 0.80 (0.73–0.86) | 0.57 (0.49–0.65) | 0.57 (0.50–0.64) | |
| VSD (Retina) | 0.55 (0.45–0.66) | 0.75 (0.67–0.82) | 0.70 (0.61–0.79) | 0.68 (0.60–0.76) | 0.65 (0.58–0.72) | |||
| FAZ area | 0.62 (0.57–0.67) | 0.55 (0.45–0.65) | 0.60 (0.52–0.69) | 0.55 (0.45–0.65) | 0.62 (0.54–0.71) | 0.61 (0.52–0.69) | 0.67 (0.60–0.74) | 0.56 (0.49–0.63) |
| FAZ perimeter | 0.65 (0.60–0.71) | 0.54 (0.43–0.64) | 0.61 (0.52–0.69) | 0.57 (0.48–0.70) | 0.66 (0.58–0.74) | 0.55 (0.47–0.63) | 0.71 (0.64–0.78) | 0.57 (0.49–0.64) |
| FAZ circularity | 0.72 (0.67–0.78) | 0.51 (0.40–0.61) | 0.64 (0.56–0.73) | 0.63 (0.54–0.73) | 0.75 (0.67–0.83) | 0.52 (0.43–0.60) | 0.77 (0.70–0.83) | 0.55 (0.48–0.63) |
| All parameters combined | 0.62 (0.49–0.75) | 0.70 (0.57–0.82) | 0.71 (0.63–0.80) | 0.71 (0.63–0.78) | ||||
| VD (SCP) | 0.74 (0.68–0.80) | 0.60 (0.47–0.74) | 0.72 (0.63–0.81) | 0.63 (0.52–0.75) | 0.74 (0.65–0.83) | 0.52 (0.43–0.62) | 0.61 (0.52–0.70) | |
| VD (DCP) | 0.72 (0.66–0.78) | 0.57 (0.43–0.71) | 0.71 (0.61–0.80) | 0.65 (0.53–0.76) | 0.73 (0.64–0.81) | 0.52 (0.43–0.62) | 0.80 (0.73–0.87) | 0.54 (0.45–0.63) |
| VD (Retina) | 0.77 (0.71–0.83) | 0.57 (0.43–0.70) | 0.73 (0.64–0.82) | 0.68 (0.57–0.80) | 0.77 (0.68–0.85) | 0.54 (0.44–0.63) | 0.60 (0.51–0.69) | |
| VSD (SCP) | 0.75 (0.69–0.81) | 0.58 (0.44–0.71) | 0.73 (0.64–0.82) | 0.65 (0.53–0.77) | 0.76 (0.68–0.85) | 0.53 (0.43–0.62) | 0.61 (0.53–0.70) | |
| VSD (DCP) | 0.73 (0.67–0.78) | 0.58 (0.44–0.71) | 0.70 (0.61–0.79) | 0.63 (0.52–0.75) | 0.73 (0.64–0.82) | 0.53 (0.44–0.63) | 0.80 (0.73–0.88) | 0.54 (0.45–0.60) |
| VSD (Retina) | 0.78 (0.72–0.84) | 0.56 (0.42–0.70) | 0.74 (0.65–0.83) | 0.69 (0.57–0.80) | 0.79 (0.71–0.87) | 0.51 (0.42–0.61) | 0.60 (0.51–0.69) | |
| FAZ area | 0.58 (0.52–0.65) | 0.66 (0.54–0.79) | 0.71 (0.61–0.80) | 0.59 (0.47–0.70) | 0.58 (0.48–0.68) | 0.61 (0.51–0.70) | 0.62 (0.53–0.71) | 0.54 (0.45–0.62) |
| FAZ perimeter | 0.61 (0.55–0.65) | 0.69 (0.57–0.81) | 0.72 (0.63–0.81) | 0.57 (0.45–0.69) | 0.64 (0.54–0.73) | 0.56 (0.46–0.65) | 0.66 (0.57–0.75) | 0.52 (0.43–0.61) |
| FAZ circularity | 0.68 (0.62–0.74) | 0.63 (0.49–0.77) | 0.66 (0.57–0.76) | 0.54 (0.43–0.67) | 0.58 (0.48–0.68) | 0.57 (0.48–0.67) | 0.74 (0.67–0.82) | 0.54 (0.45–0.62) |
| NPA | 0.57 (0.43–0.70) | 0.71 (0.62–0.79) | 0.67 (0.61–0.77) | |||||
| All parameters combined | 0.74 (0.67–0.81) | |||||||
| All parameters combined except NPA | 0.76 (0.65–0.87) | 0.72 (0.61–0.84) | 0.75 (0.67–0.83) | 0.71 (0.63–0.79) | ||||
| All parameters | ||||||||
The AUC values >0.8 are highlighted in bold. AUC = area under the curve; CI = confidence interval; DCP = deep capillary plexus; DR = diabetic retinopathy; FAZ = foveal avascular zone; NPA = nonperfusion area; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; SCP = superficial capillary plexus; VD = vessel density; VSD = vessel skeletonized density.
Figure 5Receiver operating characteristic (ROC) analyses comparing the accuracy of each quantitative metric for predicting the presence of diabetic retinopathy (DR) for (A) on 6 × 6 mm angiogram size and (B) 12 × 12 mm angiogram size. C, Combined ROC analyses comparing the accuracy of all quantitative metrics on 6 × 6 mm and 12 × 12 mm angiograms for predicting the presence of DR. The numbers signify the area under the curve (AUC) value. The dashed line represents the trade-off resulting from random chance. DCP = deep capillary plexus; FAZ = foveal avascular zone; NPA = nonperfusion area; SCP = superficial capillary plexus; VD = vessel density; VSD = vessel skeletonized density. 6 × 6 and 12 × 12 refer to the angiogram sizes in mm × mm.